Lu AF11167

DRUG5 trials

Sponsors

H. Lundbeck A/S

Conditions

HealthySchizophrenia

Phase 1

Study to Evaluate the Effect of a Known and Marketed Product, Itraconazole (Mycosis Treatment) on Lu AF11167 Entering the Body and Subsequently Elimination. The Study is a Drug-drug Interaction Study in Healthy Volunteers.

CompletedNCT02199431

H. Lundbeck A/SHealthy

Start: 2014-07-31Updated: 2015-09-21

Safety and Tolerability Study of Lu AF11167 After Repeated Dosing in Patients With Schizophrenia

CompletedNCT02202213

H. Lundbeck A/SSchizophrenia

Start: 2013-10-31Updated: 2015-02-18

Pharmacokinetic Properties of Various Modified Release Tablet Formulations of Lu AF11167

CompletedNCT02260830

H. Lundbeck A/SSchizophrenia

Start: 2014-08-31Updated: 2015-03-06

A Study Investigating Tablet Formulations of Lu AF11167 in Healthy Subjects

CompletedNCT04104503

H. Lundbeck A/SHealthy

Start: 2019-09-17End: 2020-04-09Updated: 2020-04-17

Phase 2

Flexible-dose Long-term Extension Study of Lu AF11167 in Patients With Schizophrenia With Prominent Negative Symptoms

TerminatedNCT03929497

H. Lundbeck A/SSchizophrenia

Start: 2019-04-22End: 2020-09-14Updated: 2020-09-23

Related Papers

A double-blind, randomized, placebo-controlled proof of concept study of the efficacy and safety of Lu AF11167 for persistent negative symptoms in people with schizophrenia.

2022-06-1211 citations